dna-image.jpg
Biotech

Coronavirus test maker Oxford Nanopore eyes $5.2B price tag for IPO

Biotech startup Oxford Nanopore could hit a valuation of up to $5.2 billion when it goes public via a rare London IPO in October.
Oxford Nanopore develops portable DNA/RNA sequencers that provide real-time biological data analysis.
(OsakaWayne Studios/Getty Images)


Oxford Nanopore, a VC-backed biotech startup that made a name for itself during the pandemic by developing testing kits for coronavirus, could hit a valuation of up to £3.8 billion (about $5.2 billion) when it goes public via a rare London IPO in October, according to reports.

The startup is planning to set a range of 375 pence to 450 pence per share, according to terms seen by Bloomberg, with a free float of at least 25%. Earlier filings show that the company is aiming to raise £300 million in gross proceeds with a secondary offer of existing shares.

The DNA/RNA-sequencing company—which is backed by IP Group, Tencent and Temasek—will be the 11th UK-based startup in the biotech and pharmaceutical space to have gone public since the start of 2020, according to PitchBook data. However, six of those opted to go public in the US. Among them is drugmaker Immunocore, which raised $273 million in its February listing. In May, Oxford-AstraZeneca COVID-19 vaccine co-inventor Vaccitech secured $110.5 million in its Nasdaq debut.

Higher demand for biotech and pharmaceuticals in the US has continuously driven UK companies to go public across the Atlantic. The Nasdaq has historically been the exchange of choice where companies have access to a larger and more experienced base of investors than in the UK, as well as higher valuations.

“We think it’s an urban myth that our sector does better on Nasdaq,” Oxford Nanopore CEO Gordon Sanghera said in a conference call following the ITF announcement. “We, as a company, are already a global tech player, we sell into 100 countries globally, we have a great shareholder base, which is global. When we did the analysis, the investors that we will get in London were of a similar quality to the ones that you would pick up in Nasdaq. That’s how we ended up picking London.”

More onerous listing rules around share structures and liquidity requirements have also deterred UK companies from staying at home, but recent changes toward relaxation may increase London’s attractiveness for biotech and pharma companies—and Oxford Nanopore is taking advantage.

The startup has decided to adopt a structure under which Sanghera will receive a special class of shares with enhanced power designed to veto an unwanted takeover. This is of particular importance in the current climate as this year has seen a high level of interest in UK-listed entities as takeover targets. However, unlike the dual-class share structures used by companies such as Deliveroo, Sanghera will not have additional voting rights.

Learn about our editorial standards.